U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector transforms.
Related Posts
China vows ‘more proactive’ fiscal stimulus measures, ‘moderately’ looser monetary policy
China’s leaders pledged “more proactive” fiscal and monetary policies next year to boost domestic consumption, according to an official readout.
Markets are getting more comfortable again with the idea of a December rate cut
Traders a week ago had taken the possibility of a cut this month down to around a coin flip.
JPMorgan upgrades this beaten-down industrial salt stock, says it’s primed for a major turnaround
Analyst Jeffrey Zekauskas upgraded the stock to overweight from neutral.